The approval, which marks the first for a once-daily, single-tablet combination therapy for pulmonary arterial hypertension, is based on findings from the phase 3 A DUE study. The combination is ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. New data from an extension study of the PHIRST trial ...
GSK today announced that the first phase IIIb/IV study, conducted in collaboration with Gilead Sciences Inc., to investigate combination therapy of ambrisentan and tadalafil in treatment naïve ...
October 30, 2008 (Philadelphia, Pennsylvania) — The phosphodiesterase type 5 inhibitor tadalafil (Cialis, Eli Lilly & Co) showed strong and durable efficacy, safety, and tolerability in the treatment ...
May 28, 2009 (Bologna, Italy) — The Food and Drug Administration has approved tadalafil (Adcirca, United Therapeutics) for the treatment of pulmonary arterial hypertension (PAH). The drug, a ...
BEERSE, BELGIUM , Sept. 30, 2024 (GLOBE NEWSWIRE) -- – Janssen-Cilag International NV, a Johnson & Johnson company, announced today that the European Commission (EC) has approved Yuvanci ® (macitentan ...
Tadalafil 40 mg is indicated in the U.S. and the EU to improve exercise ability and capacity, respectively. Preclinical data have suggested these therapies may have synergistic effects. However, ...
Patients with pulmonary arterial hypertension (high blood pressure in the arteries that supply the lungs, also called PAH) had approximately double the reduction in pulmonary vascular resistance (PVR) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results